Clarity Pharmaceuticals (ASX:CU6) Non Operating Income: A$4.90 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
30 GF Score
Price A$2.69
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Non Operating Income?

Clarity Pharmaceuticals ASX:CU6 +0.37% 30 Non Operating Income is A$4.90 Mil as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Clarity Pharmaceuticals's Non Operating Income for the six months ended in Dec. 2025 was A$3.05 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was A$4.90 Mil.

Clarity Pharmaceuticals Non Operating Income Related Terms

Clarity Pharmaceuticals Non Operating Income Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Non Operating Income Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Non Operating Income
6.46 9.80 11.51 9.92

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.42 6.09 8.07 1.85 3.05
ASX:CU6
30GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$4.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of A$4.90 Mil mean?
Clarity Pharmaceuticals (ASX:CU6) has a Non Operating Income of A$4.90 Mil as of Dec. 2025. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Non Operating Income too high?
Clarity Pharmaceuticals' current Non Operating Income is A$4.90 Mil. Overall, Clarity Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Non Operating Income compare to VRTX and REGN?
Clarity Pharmaceuticals' Non Operating Income of A$4.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Non Operating Income is A$4.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Non Operating Income of A$4.90 Mil. The current Non Operating Income is A$4.90 Mil. Clarity Pharmaceuticals' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Non Operating Income is A$4.90 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
30GF Score

Get the complete analysis for ASX:CU6

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.69
Price